The Effectiveness of SGLT2 Inhibitors in CKD Patients

Abstract

Sodium-glucose cotransporter-2 inhibitors, often known as SGLT2Is, are a class of medications used largely for anti-diabetic activity in oral dose form that lowers blood glucose levels. In recent years, numerous trials have documented the use of medications for conditions including renal and cardiovascular illness that go beyond only decreasing blood sugar. Other benefits of SGLT2Is' glucose-lowering activities include slowing or halting the progression of chronic kidney disease, lowering estimated glomerular filtration rate, lowering albuminuria, improving renal and cardiovascular health, and reducing estimated glomerular filtration rate. Published clinical trials reported all of these SGLT2I effects. The studies that we reviewed for this article are the Canagliflozin CardioVascular Assessment Study (CANVAS), Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE), Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA - CKD) trial, Effects of SGLT2I dapagliflozin on Proteinuria in Non-Diabetic Patients with The clinical studies, SGPLT2I class of medications, and their impact on cardiovascular and renal illnesses in diabetic and non-diabetic individuals are adequately covered in this review study.
 Keywords: SGLT2Is, Chronic kidney disease, dapagliflozin, Canagliflozin

Diabetic kidney disease: Risk factors, challenges and opportunities in the era of precision medicine

“…For instance, they momentarily reduce GFR [86] diminish albuminuria, likely by enhancing the tubuloglomerular feedback pathway. [87]. The Empagliflozin, Cardiovascular Outcomes, and Mortality in DM2 (EMPA-REG OUTCOME) Study, which randomised 7020 individuals with type 2 diabetes and cardiovascular disease to the SGLT-2 receptor empagliflozin at two doses versus placebo, provides the most compelling evidence for renoprotection.…”